A neutralizing monoclonal antibody targeting the acid-sensitive region in chikungunya virus E2 protects from disease.
The mosquito-borne alphavirus, chikungunya virus (CHIKV), has recently reemerged, producing the largest epidemic ever recorded for this virus, with up to 6.5 million cases of acute and chronic rheumatic disease. There are currently no licensed vaccines for CHIKV and current anti-inflammatory drug tr...
Main Authors: | Suganya Selvarajah, Nicole R Sexton, Kristen M Kahle, Rachel H Fong, Kimberly-Anne Mattia, Joy Gardner, Kai Lu, Nathan M Liss, Beatriz Salvador, David F Tucker, Trevor Barnes, Manu Mabila, Xiangdong Zhou, Giada Rossini, Joseph B Rucker, David Avram Sanders, Andreas Suhrbier, Vittorio Sambri, Alain Michault, Marcus O Muench, Benjamin J Doranz, Graham Simmons |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2013-01-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC3772074?pdf=render |
Similar Items
-
Chikungunya virus, risks and responses for Australia
by: Andreas Suhrbier, et al.
Published: (2016-06-01) -
Early events following murine gammaherpesvirus (MHV-68) infection
by: Selvarajah, Suganya
Published: (2001) -
Neutralizing Monoclonal Antibodies Block Chikungunya Virus Entry and Release by Targeting an Epitope Critical to Viral Pathogenesis
by: Jing Jin, et al.
Published: (2015-12-01) -
Effective chikungunya virus-like particle vaccine produced in insect cells.
by: Stefan W Metz, et al.
Published: (2013-01-01) -
Granzyme A in Chikungunya and Other Arboviral Infections
by: Alessandra S. Schanoski, et al.
Published: (2020-01-01)